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Techniques to measure the proliferation rate of human tumours in
situ have been sought for decades. Historically, estimates were
based on the fraction of mitoses visible in histological specimens.
In the 1950s, radioactive precursors of DNA were used to identify
the cells preparing for division and the four separate phases of the
cell cycle were identified, G1, S, G2 and M (Howard and Pelc,
1953). This was followed in the 1960s by techniques to measure
the cell cycle, the growth fraction and the rate of cell loss in order
to provide a complete description of the growth characteristics
of experimental and human tumours (reviewed in Steel, 1977).
Unfortunately, these techniques required multiple biopsies and the
DNA targeted radio-isotopes were not suitable for widespread use
in humans, because of their genotoxic potential.
In the 1970s, flow cytometers were manufactured and the frac-
tion of cells in the S phase could be identified without adminis-
tering precursors, by staining cells for their DNA content and
counting those between diploid and tetraploid DNA content.
However, this does not give kinetic information about transit times
and cannot distinguish between active and quiescent S phase cells.
Eventually, in the early 1980s, non-radioactive halogenated
precursors were developed that could, when bound into DNA, be
identified using monoclonal antibodies with fluorescent tags
(Gratzner et al, 1982; Dolbeare and Gray, 1983). It was realized
that this provided the potential to measure both the fraction of cells
actively synthesizing DNA and their rate of progress through the S
phase from a single biopsy sample (Begg et al, 1985). It was called
the relative movement assay. This made it possible, at last, to
obtain from a single biopsy in patients the two independent para-
meters, Ts and labelling index (LI), that are needed to estimate the
potential doubling time, Tpot, of a tumour.
l is a correction factor for the non-linear age distribution, and is
often arbitrarily (as in our centre) set at 0.8. There are, inevitably,
a number of assumptions in applying this technique, and a certain
degree of compromise in the time interval that must be used
between labelling and sampling the cells. A very short interval
(0.5–1.0 h) is optimal for determining LI, but an interval that is
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Summary The advent of halogenated pyrimidines (bromodeoxyuridine, BrdU; idoxuridine, IdU) and antibodies to recognize them has opened
new horizons for the measurement of proliferation in human tumours. These precursors of DNA can be given to patients and a single biopsy
can be taken to measure in a flow cytometer both the fraction of labelled cells and their rate of movement through the S phase. From these
two parameters the potential doubling time, TPOT, can be calculated. To measure both parameters simultaneously a compromise is made in
the time of assessing the labelling index (LI). LI should ideally be assessed after a very short interval, e.g. 0.5–1 h, to avoid the contaminating
influence of any cells dividing between injection and biopsy. However, an interval of 4–8 h is considered necessary to assess TS from the
relative movement of cells through the S phase. Several techniques exist to correct for cell division if the interval is long. The simplest
correction, which only corrects for the division of labelled cells, is most widely used. Downward correction factors of at least 10% are
commonly applied, reducing the observed LI values. In this paper we illustrate graphically the dependence of the appropriate correction factor
on various cell kinetic parameters. The duration of G2 is the most critical parameter for both the size and direction of any correction factor. The
G2 phase has previously been shown to be about three times longer in human tumours than in rodents. If G2+M is as long as 6 h, the main
artefact of the intervals between injection and biopsy up to 7 h is that the observed LI is too low because of division of unlabelled G2 cells. A
correction of up to 10% is needed but in an upward direction. A nomogram of probable correction factors as a function of sampling interval is
provided. We show from flow cytometric data that G2+M may be shorter than 4 h for head and neck tumours. It is recommended that the
correction factor established by gating the flow histogram should always be checked against this nomogram, or that no correction factor
should be applied. We have used this mathematical approach to re-evaluate two sets of published LI data for rectal and colorectal tumours.
We show that the mathematical correction of each data point leads to a 30% increase in the median value, compared to the simple gating
procedure. We question whether other of the published series of LI values gained with BrdU or IdU may also substantially underestimate the
true LI values, if a simple gating procedure has been used in an attempt to reduce the impact of divided S phase cells.
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Ts
Tpot = l Æ (Steel, 1977) (1)
LIabout half TS is optimal for defining the relative movement of
labelled S phase cells towards a G2 content of DNA. An interval
of 4–8 h is generally recommended. For cells in vitro or in rodent
tumours, this interval is much longer than the phases (G2 plus
M). This interval would, in such systems, allow labelled cells to
transit these phases and divide, thus adding extra labelled cells to
the population. This potential artefact in the assessment of LI
was recognized early on, and several methods have been offered
to solve it. The first was a simple and practical gating procedure
of the bivariate histogram (Begg et al, 1988). The labelled cells
are assessed in the flow cytometry histogram, and a decision is
made about which cells have transited G2 and mitosis and re-
entered G1 as two cells. This group of cells is then gated and
counted separately, divided by two and subtracted from both the
labelled cells and the total cells to obtain a corrected LI (see
Begg, 1989, for details). No account was taken of the division of
unlabelled cells leaving G2 and doubling as they go through
mitosis, because for cells in vitro and for animal tumours these
phases are very short.
A modification of this formula was proposed by Brons et al
(1992) to take into consideration the division of unlabelled G2
cells within an interval corresponding to G2+M. Although this is
more accurate, the simple formula is more commonly applied. It
has been pointed out that the simple (Begg) correction is inappro-
priate for very short sampling times or for histograms where there
is not clear evidence of two separate sub-populations in the
bivariate histograms (Wilson et al, 1988; Begg, 1989). However,
in practice, in many centres as in ours it may be applied somewhat
too frequently.
An alternative and more sophisticated approach is to use a much
more complex mathematical treatment of the measured LI. This
involves assumptions or prior knowledge about the phase duration
and the form of the growth curves (White et al, 1990; Johansson
et al, 1998). The mathematical correction is more accurate but
appears somewhat complex and has not been widely adopted by
flow cytometry operators.
In this paper we demonstrate graphically the correction factors
that should theoretically be applied for various assumptions about
phase durations. We show the consequences for different values of
LI. We have used the same mathematical model as that of White et
al (1990). We have then used this approach to re-evaluate two sets
of our own published proliferation data for colorectal cancers. We
demonstrate the difference if the commonly used simple correc-
tion, or the mathematical formula based on best estimates of the
duration of G2 and S in human tumours is applied.
MATERIALS AND METHODS
There are two parts to this study: a mathematical component, and
a practical analysis of patient data.
Mathematical modelling
A flash label is assumed to be administered which marks only
those cells actively synthesizing DNA. As the cells progress
around the cell cycle, first unlabelled cells (originally in G2 and M
phase) then labelled cells (originally in S phase) divide, and there-
fore the fraction of labelled cells (f l) varies with time. As
described by White et al (1990), this fraction can be calculated at
any time t after labelling, according to
where TC, TG2+M and TS are the durations of the total cell cycle, or
the individual phases (G2+M) and S, which must be estimated
experimentally or assumed. If p is the probability that a new cell is
proliferating, then
p = 1 corresponds to a growth fraction of 1, which is what we have
assumed in this study. If a growth fraction less than unity is
assumed it does not change any of the conclusions for time inter-
vals less than G2+M+S. Equation (2) can then be used to calculate
f l(t) for any time t after injecting the stain. It is also possible to
solve for TC for a known f l(t) and t, with an assumed TS and TG2+M.
Then, by setting t = 0, one can calculate the true LI.
Analysis of human tumours
We have taken two sets of flow cytometry data for human tumours
that have already been published (Bergström et al, 1998;
Palmqvist et al, 1998). We have re-considered the data from
bivariate histograms, i.e. the corrected LI and the correction factor.
These were originally obtained by gating labelled cells that were
considered by the FCM operator to have divided in the interval
between administering the precursor and surgical excision. Using
the simple practical correction, these gated labelled G1 cells were
halved (to correct for division) and subtracted from both the
numerator and the denominator to obtain LI corrected. The two
data sets have now been re-analysed. Using the actual raw count of
LI a theoretical correction was applied from equation 2, calculated
for the specific time from injection to surgery for that sample.
In order to undertake this more complex mathematical model-
ling it is necessary to specify the appropriate values for the cell
cycle phase durations. These are listed in Table 1 for spontaneous
human tumours and for a range of experimental models, deter-
mined by the per cent labelled mitosis method (Steel, 1977). The
combined duration of the phases (G2 and mitosis) is the most
important parameter for the present purposes, since cells labelled
while in the S phase must transit these phases before appearing as
two cells in G1. Using the per cent labelled mitosis curve method,
TG2+M was found to be approximately three times longer in human
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ec(TG2+M–t) (ecTs–1) if  t ≤ TG2+M
fl (t)={
1 + ec(TG2+M–t) (ecTs – 2) if TG2+M ≤ t ≤ TS + TG2+M (2)
2ec(TG2+M–t) (ecTs –1) if TS + TG2+M ≤ t ≤ TC + TG2+M
ln(2p)
c = · (3)
TC
Table 1 Average estimates of cell cycle phase durations obtained with the
per cent labelled mitosis technique in solid tumours (from Steel, 1977)
Tumour type G1 (h) S (h) G2a (h) LI (%)
Human tumours 22 (8–38) 16 (10–24) 6 (2–10) 19 (4–29)
Frequently passaged mouse 4 (2–7) 9 (6–12) 2 (1–5) 32 (12–68)
tumours
Frequently passaged tumours 11 (4–39) 8 (5–10) 3 (1–4) 20 (10–36)
in rats and hamsters
Early transplants of tumours 13 (4–48) 11 (4–18) 2 (1–4) 18 (5–45)
in rats and mice
Primary tumours (animals) 13 (2–36) 8 (5–11) 3 (1–6) 14 (6–31)
aTime in mitosis is approximately 1 h in experimental systems. Arithmetic
mean of quoted values with range shown in brackets.tumours (mean value 6 h) than in rodents. Using flow cytometry
techniques somewhat shorter TG2+M estimates have been found,
e.g. 4.5 h (Begg, 1989). A range of possible TG2+M values have
therefore been used for our calculations.
RESULTS
Figure 1 illustrates the cyclic fluctuations in the observed LI
values if the interval between labelling and sampling is varied
between 1 h and 30 h. In this first example we have used represen-
tative values for LI of 15%, TG2+M of 6 h and TS of 15 h. The upper
panel (Figure 1A) shows that the LI falls from the starting value of
15% for a period corresponding to TG2+M, during which time unla-
belled cells are being added by cell division. After 6 h this reverses
and the LI then increases over the next 15 h as labelled cells
divide. Subsequently, as G1 cells begin to enter mitosis, the unla-
belled cells increase again. The observed LI falls back towards the
starting value, which it will reach after one complete cell cycle or
potential doubling time unless there is a differential cell loss from
a specific phase. The lower panel shows the correction factor that
needs to be applied to convert the observed value at any particular
time back to the original starting value (of 15%). It is the converse
of the LI fluctuations. Figure 1B illustrates clearly that a factor
above unity is needed to correct the LI value upward over the first
6 h (i.e. TG2+M) because of addition by division of unlabelled cells.
In this example, only after 7 h is a downward correction needed.
Figure 2 shows how the correction factor depends upon the
chosen parameters. In general, the default values for these calcula-
tions have been set at LI0 = 15%, TG2+M = 6 h and TS = 15 h. In each
panel two of these parameters are kept constant and the third is
varied systematically to determine its impact. The graphical
display is now limited to the region of clinical interest, i.e. the first
10 h. (The recommended interval between labelling and obtaining
the tumour specimen by biopsy or surgery is 4–8 h.)
Figure 2A shows the major influence of the duration of G2+M.
Unlabelled cells transit mitosis and produce an artificial reduction
in the observed LI for a period that is a little longer than TG2+M.
Thus a positive correction is needed to increase LIT to its original
value for longer intervals if the duration of TG2+M is longer.
The correction factor is small, and does not reach 10% in these
examples.
Figure 2B shows that the value of TS has no influence on the
time period for which an upward correction is needed, but it does
have an influence on the magnitude of the actual correction factor.
Labelling indices in human tumours 1637
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Figure 1 Schematic illustration of the influence of cell division in the interval
between injection of the labelled DNA precursor and surgery. (A) The
fluctuation in the observed LI with time for an assumed initial LI0 of 15%, if
TG2+M = 6 h and TS = 15 h. Initially, the observed LI drops, as unlabelled G2
cells divide, and then increases as cells originally labelled in S pass through
mitosis. (B) This leads to fluctuations in the factor needed to convert the
observed LI at time T to the true LI at time = 0. An upward correction (> 1.0)
is needed at times shorter than TG2+M.
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Figure 2 Schematic illustration of the influence on the correction factor for
different time intervals of various cell kinetic parameters. (A) Variation of
TG2+M for a constant TS = 15 h, LI0 = 15% influences both the timing of the
inversion from a positive to a negative correction factor, and the maximum
magnitude of the positive correction factor. (B) Variation of TS for a constant
TG2+M = 6 h, LI0 = 15% has a direct influence on the magnitude of the
correction factor, but not on the timing of the inversion. (C) Variation of initial
LI for constant TS = 15 h, TG2+M = 6 h. The magnitude of the upward
correction to counteract addition of unlabelled cells by division is increased
with higher values of LIFor this threefold change in TS the correction factors are all small
(≤ 10%), but positive, for a little longer than the duration of
G2+M.
Figure 2C shows the impact of the choice of LI0 for these
schematic illustrations. The correction factor in the early time
intervals varies in proportion to the fraction of unlabelled cells at
the start. For higher LI0 values, unlabelled cells are rarer, and the
addition of extra unlabelled cells from G2 has a greater impact.
The magnitude of the correction is directly proportional to LI0 and
stays positive for a longer time with higher labelling indices.
Table 2 is a nomogram which shows the correction factors that
should be applied for intervals of 2–8 h for initial LI ranging from
5–35%. This has been constructed on the assumption of phase
durations being TS = 15 h and TG2+M = 6 h in the upper panel, 4.5 h
in the middle panel and 3.0 h in the lower panel. The important
feature of Table 2 is that almost all the correction factors listed are
greater than unity and illustrate the frequent need to correct
upwards, not downwards, especially if TG2+M is longer than 3 h.
Figure 3 illustrates two sets of experimental data obtained with
a flow cytometer from individual patients in Umeå after surgical
excision of colon tumours. In the left-hand panels the tumour was
removed at a very short interval (1.2 h), whereas in the right-hand
panels the sample was taken 6.4 h (i.e. within the recommended
range) after administering 100 mg IdU intravenously to the
patient. The vertical axis reflects fluorescence which is propor-
tional to IdU incorporation. The horizontal axis represents
propidium iodide fluorescence, which indicates the DNA content.
The frames that are shown were those applied routinely by the
flow cytometry operator, who had no knowledge of the interval
between injection and surgery. Since it has been specified that the
appearance of a subset of divided labelled cells is a necessary
‘quality control’ feature for the relative movement assay (Begg,
1989) an effort is always made to identify and gate out the G1 cells
in the bivariate histograms. In the left-hand histogram, although
there is no clear margin between the two gates, they have never-
theless been defined, setting a gate over the G1 peak. We now
believe that the frame applied in the left hand panel is inappro-
priate because it assumes cell division of labelled cells in an
interval that is too short to allow that. These cells must be undi-
vided early S phase labelled cells. In this very short interval
between labelling and surgical excision, it is extremely unlikely
that any labelled cells could have traversed G2 and mitosis. In the
right-hand panel, by contrast, there is a clear zone between the two
clouds of labelled cells, and this histogram shows that a significant
fraction of S phase cells have divided in this tumour within 6.4 h.
These gating procedures, as shown, are routinely applied within
our pathology department.
We have taken two recently published sets of data from our
institution in which we have re-evaluated each flow cytometry
histogram to obtain each raw uncorrected value of LI. We have
then replaced the simple gating correction factors with those
calculated as in Table 2. Figure 4 shows the factors that were
originally applied by FCM gating to correct each data point in
these two published series of colon and rectal tumours. They range
from 0.63 to 0.95 and show remarkably little dependence upon the
time interval between injection and tumour excision. The bold
solid line shows the correction factor that should theoretically
apply if TG2+M = 6 h, TS = 15 h and LI0 = 15%. The other lines
show the correction factors if TG2+M is as short as 4.5 or even 3 h. It
is clear that almost all of the correction factors that were applied
by the simple gating procedure are in disagreement with the more
precise mathematical prediction. Even if the G2+M were as short
as 3 h (lower dashed line), all but three of the correction factors
should not be as low as those that have in practice been applied.
Figure 5 illustrates the individual LI values obtained with the
two different methods of correcting for cell division. In the left
hand panels the data are illustrated, divided according to the time
interval, for short, average and long intervals. There is a consistent
deviation of the points away from the 1:1 correlation independent
of the interval between injection and surgery. The right hand
panels show that the rank order is similar but not identical for the
LI corrected by the two methods.
Figure 6 illustrates the consequence of these two different
approaches to correcting LI and compares them with the raw data.
Cumulative frequencies of LI are shown, and the median value is
indicated at 50% on each curve. Figure 6A represents 34 rectal
carcinomas and Figure 6B 53 colon carcinomas. The median LI
values corrected by the mathematical modelling technique are
almost identical to the raw data. However, the median values after
correction by the FCM gating technique are 27–31% lower
compared with the original raw data. The progressive separation of
the curves at higher values of LI shows the increasing influence of
the addition of unlabelled cells by division at early times if they
are relatively rare in the population. Figure 6 clearly demonstrates
that for these two sets of data the raw uncorrected LI are more
accurate than those to which the simple FCM gating correction has
been applied.
The means and ranges derived from the publications where
these data were originally reported are summarized in Table 3
(rectal tumours, Bergström et al, 1998, and colorectal tumours,
1638 C Bergström et al
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Table 2 Nomogram to illustrate correction factors calculated for a range of
LI values and sampling times
TG2+M = 6 h
LI = 5% 10% 15% 20% 25% 30% 35%
Time
2 h 1.01 1.02 1.02 1.03 1.03 1.04 1.04
3 h 1.01 1.03 1.03 1.04 1.04 1.05 1.06
4 h 1.03 1.03 1.04 1.05 1.06 1.07 1.08
5 h 1.03 1.04 1.05 1.06 1.08 1.09 1.10
6 h 1.04 1.04 1.06 1.08 1.10 1.11 1.13
7 h 0.98 0.99 1.01 1.02 1.05 1.06 1.08
8 h 0.92 0.93 0.96 0.97 1.00 1.02 1.04
TG2+M = 4.5 h
LI = 5% 10% 15% 20% 25% 30% 35%
Time
2 h 1.01 1.02 1.02 1.03 1.03 1.04 1.04
3 h 1.03 1.03 1.03 1.04 1.05 1.05 1.06
4 h 1.03 1.03 1.04 1.05 1.06 1.07 1.08
5 h 1.00 1.00 1.02 1.03 1.05 1.06 1.07
6 h 0.94 0.95 0.97 0.98 1.00 1.02 1.03
7 h 0.89 0.90 0.92 0.94 0.96 0.97 0.99
8 h 0.85 0.86 0.87 0.89 0.92 0.93 0.95
TG2+M = 3 h
LI = 5% 10% 15% 20% 25% 30% 35%
Time
2 h 1.02 1.02 1.03 1.03 1.03 1.04 1.04
3 h 1.03 1.02 1.03 1.04 1.05 1.05 1.06
4 h 0.97 0.97 0.98 0.99 1.00 1.01 1.02
5 h 0.91 0.92 0.93 0.94 0.96 0.97 0.98
6 h 0.87 0.87 0.88 0.90 0.92 0.93 0.95
7 h 0.82 0.83 0.84 0.86 0.88 0.90 0.91
8 h 0.77 0.79 0.80 0.82 0.84 0.86 0.88Palmqvist et al, 1998). The choice of correction factor makes a
substantial difference to the conclusion about the mean LI and the
range in both these data sets. The mathematically corrected LI
values do not change much even if G2+M is varied between 3 and
6 h. They are all quite close to the uncorrected value and differ
markedly from those derived with a simple FCM correction. This
indicates that less error is introduced if no correction factor is
applied.
DISCUSSION
The technical innovation of being able to use a single biopsy to
simultaneously measure Ts and LI has made it possible to accumu-
late a large amount of data on human tumour cell kinetics. Many
thousands of patients have now received one of the halogenated
pyrimidines and most of the studies have shown that the LI is very
variable from patient to patient, and from one histological type and
Labelling indices in human tumours 1639
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Figure 3 Two examples of bivariate flow cytometry histograms of colon carcinomas from the series of colorectal cancers published by Palmqvist et al (1998).
Corresponding DNA histograms are shown below. The gates applied according to the routine procedures are indicated. (A, C) short interval of 1.2 h. (B, D) long
interval of 6.4 h. A subset of idoxuridine (IdU) labelled cells was gated by the operator in both panels as representing divided labelled cells (gate 1), and
correction factors of 0.89 were derived from both histograms.
Table 3 Summary of labelling indices from two published studies, together with the FCM gating correction and three theoretically
calculated values (using equation 2)
53 colon cancer patients (from 34 rectal cancer patients (from
Palmqvist et al, 1998) Palmqvist et al, 1998;
Bergström et al, 1998)
Mean Median Range Mean Median Range
Observed plc (raw data) 13.3 11.6 2.4–42.6 16.7 15.1 2.6–55.4
Mathematical correction if 12.4 9.8 2.1–40.3 15.8 13.4 2.1–56.3
TG2+M = 3
TG2+M = 4.5 13.3 10.6 2.3–40.3 16.9 14.7 2.4–61.1
TG2+M = 6 13.8 11.5 2.5–48.0 17.7 15.6 2.7–65.6
With FCM gated CF 9.7 8.5 1.8–32.8 12.3 10.8 1.7–45.7site to another (e.g. Rew et al, 1991; Bennett et al, 1992; Wilson et
al, 1993a, 1993b; Begg, 1995; Terry et al, 1995; Bergström et al,
1998; Palmqvist et al, 1998). The flow cytometric estimates of the
potential doubling time from these relative movement assays show
that the median Tpot is around 4–7 days for most tumour types, but
with a spread from 1 to 30 or more days. The duration of Tpot is
directly linked to the estimate of LI. Thus any underestimate of LI,
because of the inappropriate use of the simple gating correction
factor would translate into a corresponding overestimate of the
potential doubling time. This is a minor variation compared with
the 10- to 20-fold difference from volume doubling times but still
may be important for practical purposes. The absolute values of
Tpot are now being built into many predictive models of the conse-
quences of fractionation using shorter treatment schedules (e.g.
Fowler and Lindström, 1992). Tumours are sometimes classified
as ‘fast’ if their Tpot value is shorter than 5 days and ‘slow’ if it is
longer. The systematic ‘down correction’ of LI would change the
proportions in these two categories and hence the need for selec-
tion of patients for accelerated regimes.
Several large studies are in progress to evaluate the relationship
between the estimate of LI or Tpot and the outcome of treatment
with either a conventional or an accelerated regime (e.g. Begg et
al, 1999; P Coucke et al, unpublished data). These are designed to
determine whether these kinetic parameters are useful prognostic
or predictive markers. The ultimate goal is to be able to identify
those patients at most risk of proliferation during a course of
therapy and select those for an accelerated regime. For this reason
it is very important to avoid random or systematic errors creeping
into the measurements, or differences in analytical procedures
from one centre to another.
It has long been recognized that the long interval needed
between injection and sampling of the tumour for the relative
movement assay may necessitate a correction of LI (Begg, 1989).
The simple practical solution that is commonly applied, however,
totally ignores the contribution of unlabelled G2 cells as they
divide. It focuses only on the artefact of additional labelled cells,
as those from the labelled compartment transit through G2 and
mitosis. It has been stressed that this is inappropriate if the time
between injection and sampling is too short and will give an
underestimate (Begg, 1988; Wilson et al, 1988). It then becomes
very important to consider how short is too short, and for this
Figure 2 shows that the duration of G2+M is the crucial parameter.
Table 1, containing data from the comprehensive review by
Steel (1977), shows that the estimates obtained from human
tumours in the 1970s, using the very detailed studies of multiple
biopsies after administering tritiated thymidine, range from 2 to
10 h with an average of 6 h. Begg (1989), however, deduced a
value slightly lower than this average. He considered the fraction
of tumours with clear movement of labelled cells into G1 as a
function of the time after administering bromodeoxyuridine
(BrdU), and reported an average value of 4.5 h.
Figure 7 summarizes three sets of data from which the duration
of G2+M can also be derived. One set is from a single centre
(Amsterdam) assessment of all the tumours entered into the multi-
centre randomized EORTC accelerated radiotherapy trial (Begg et
al, 1998). It shows that about 80% of the tumours are considered to
1640 C Bergström et al
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Figure 4 Comparison of the correction factors derived from the simplified gating of the individual flow cytometry histograms (data points) with those predicted
from the theoretical analysis. Three curves are shown for TG2+M durations of 3, 4.5 and 6 h. Most of the FCM derived corrections are far below the theoretically
derived values and show no significant trend with timehave divided labelled cells in G1 by 4 h and 100% by 4.5 h. The
second set of data comes from a single-centre study in Cairo by
Awwad and colleagues, for which all the data have been analysed
in Amsterdam (unpublished). It shows 85% of the tumours having
been described as having labelled divided cells at 4 and 5 h, and all
by 5.5 h. Both data sets would imply a G2+M that is shorter than
4 h in many human tumours. The Umeå data in Figure 6 are clearly
in disagreement with those from Amsterdam since they show that
all tumours were considered to have labelled G1 cells regardless of
the interval between labelling and sampling. This is biologically
unrealistic.
The practice of gating divided labelled cells seems to differ
from centre to centre. The details of the method and the resultant
correction factor is not quoted in publications, and is therefore
Labelling indices in human tumours 1641
British Journal of Cancer (1999) 80(10), 1635–1643 © 1999 Cancer Research Campaign
50
40
30
20
10
0 0 1 02 03 04 05 0
50
40
30
20
10
0 0 1 02 03 04 05 0
Colon cancer Colon cancer
70
60
50
40
30
20
10
0
< 3 h
3–6 h
> 6 h
0 1 02 03 04 05 06 07 0
Theortical LI
Rectal cancer
L
I
 
c
o
r
r
e
c
t
e
d
 
b
y
 
F
C
M
 
g
a
t
i
n
g
70
60
50
40
30
20
10
0
Rectal cancer
0 1 02 03 0
Ranking according to theoretical LI
D C
A B
Figure 5 Individual LI values of 34 rectal tumours and 53 colon tumours obtained with the two different methods of correcting for cell division. (A, C) The time
interval between label and biopsy for individual tumours is shown (n: < 3 h, l l: 3–6 h, s: > 6 h). (B, D) The size of the bars indicates FCM corrected LI. The
bars are ranked according to theoretically calculated LIdifficult to determine from any published series. It is then impos-
sible to rederive the original values. At the Gray Laboratory the
average correction factor applied in a large series of patients is
0.88, but in 25% of the patients it is as low as 0.83 (GD Wilson,
personal communication). At Amsterdam the average correction
factor is 0.89 over a large series of patients. Table 2 would indicate
such values are only applicable at labelling times beyond 6 h if
TG2+M is 3.0 h or longer.
White and colleagues long ago recognized that any simple
correction is inappropriate and have proposed a series of more
complex formulae to correct with greater accuracy (White et al,
1990; Terry and Peters, 1995). Their approach is the same as the
one we have adopted here and requires assumptions be made about
phase length durations. They assume, however, that the duration of
G2+M is 30% of S. It is clear that their approach is more accurate
and will provide a truer estimate of the initial LI. Most of the
practitioners of flow cytometry have found the simple practical
solution more appealing than attempting to incorporate the more
complex mathematics. The use of the nomogram in Table 2 or the
curves in Figures 2 and 4 provide a simple means of checking if
the correction factor is reasonable before it is applied.
The issue of the method of correcting LI obtained at late
sampling time to the value that was relevant at time zero has
recently been addressed in detail by Johansson et al (1998). Using
data from in vitro experiments they have intercompared four
different correction techniques to see which would give the
smallest change of corrected LI with sampling time. They show
marked differences between four mathematical models, three of
which purport to correct for the addition by division of both
unlabelled (G2) cells and labelled (S) cells. There is a 20%
difference in the corrected LI that they calculate with these four
formulae. Most of the corrected values differ significantly from
the LI values they have actually observed with a very short
labelling interval. This amply illustrates the problem but does not
provide a general solution.
We have attempted in this paper to illustrate graphically the
concept behind the need for a mathematical correction factor in
order to demonstrate the parameters that influence the magnitude
of that correction. We have illustrated that the ‘simple’ correction
is unreasonable unless very short TG2+M values are relevant in
human tumours, or quite long intervals are used between labelling
and excision. Samples taken at short intervals, less than the dura-
tion of G2, are therefore most at risk from this underestimation
of LI.
When large series of patients are reported, all the information
about the details of time between injection and sampling is, of
course, lost in the averaging procedures. Figure 6 shows that the
uncorrected data are actually very close to the mathematically
corrected data, since the correction factor rarely exceeds 1.1. In
these studies, 29% of the tumour samples were taken at intervals
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Figure 6 Cumulative frequency plots of the LI for 28 rectal tumours and 53
colon tumours if expressed as the raw data from flow cytometry (––), with a
theoretical correction applied to each value (assuming TG2+M = 6 h, TS = 15 h)
(. . .), or an adjustment by gating for divided labelled cells (- - -). The raw data
are much closer to the mathematically corrected LI0 values than those
adjusted via the flow histogram. The simple correction leads to a
considerable underestimate of LI, especially at the higher values
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Figure 7 Percentage of cells with divided labelled cells in each time interval
as a function of the time of sampling. Three series are shown: l l: head and
neck cancer patients from the EORTC multicentre study, analysed in
Amsterdam. s: head and neck cancer patients from the Egyptian study,
analysed in Amsterdam. n n: patients from the colorectal series analysed in
Umeå. The time when 50% of the tumours show divided labelled cells is a
measure of the duration of G2+M. It is between 3 and 4 h for the Egyptian
series and shorter than 4 h for the EORTC studyoutside of the recommended labelling time of 4–8 h. Twenty-two
per cent were taken at shorter times and 7% at longer times. The
median time of biopsy was 5.3 h and the median correction factor
applied was 0.73. We suggest that the provision of the raw uncor-
rected data should be recommended in all publications. We also
suggest that every correction factor derived ‘blindly’ for the
sample in the flow cytometer should be cross-checked against a
nomogram such as those in Table 2 to see whether it is a reason-
able figure, taking into account the interval between injection and
surgery/biopsy. This could certainly lead to overestimations of Tpot
and a false perception of the speed of tumour cell proliferation.
CONCLUSION
We conclude that the simple application of a gating procedure to
correct LI values obtained many hours after labelling may be
hazardous. In our institute it produces a 27% reduction in the
median LI values compared with the raw data. This underestima-
tion of LI in human tumours may be a common systematic artefact
in other laboratories. We would urge those groups collecting LI
values for the assessment of their prognostic or predictive value
to reconsider the correction factors that have been applied.
Application of an inappropriate correction factor, especially for the
short sample times could reduce the apparent prognostic power of
LI as a proliferation marker, simply because any true correlation
may be obscured.
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